Jon Gelman has been named again to Best Lawyers in America®. This recognition has been bestowed upon him for almost 2 decades.
Selection to Best Lawyers® is based on an exhaustive and rigorous peer-review survey comprising more than 2.5 million confidential evaluations by the top attorneys in the country. Because no fee or purchase is required, being listed in Best Lawyers is considered a singular honor. The annual, advertisement-free publication has been described in The American Lawyer as “the most respected referral list of attorneys in practice.”
The law firm of Jon L Gelman has been listed in the 2013 ediion of Best Law Firms Rankings of U.S. News Media and Best Lawyers.
Jon L. Gelman has been named to the 2014 edition of New Jersey Super Lawyers. Each year, only 5 percent of the lawyers in the state receive this honor.
The list is published by Martindale-Hubbell®, a company rates lawyers and designates an AV® Preeminent TM Peer Review Rating, the highest rating in legal ability and ethical standards.
The US Centers for Disease Control (CDC) is coordinating a multistate investigation of meningitis among patients who received epidural steroid injections (medication injected into the spine).
How to use social media to expand your workers' compensation practice was the subject of a presentation by Jason Gelman at the American Association of Justice's annual convention in Chicago.
Jon L. Gelman has received the top rating of "Superb" from Avvo. The rating indicated a perfect score in: experience, industry recognition and professional conduct.
Tekturna®, a blood pressure drug, has been associated with potentially life-threatening side effects such as stroke, kidney injury, high potassium and low blood pressure.
In December 2011, Tekturna® manufacturer Novartis announced its decision to terminate the clinical ALTITUDE study of the blood pressure drug based on the recommendation of the independent Data Monitoring Committee (DMC) overseeing the clinical trial study.
Following a November 2011 warning issued by the European Medicines Agency (EMA), the Food and Drug Administration (FDA) decided to reevaluate the safety of Pradaxa®.
Jon L Gelman is investigating cases involving individuals who have suffered a heart attack, ischemic stroke or other cardiac condition while taking Avandia for diabetes.
Jon Gelman is investigating cases involving infant drugs manufactured by pharmaceutical company McNeil Consumer Healthcare including include certain liquid infant’s and children’s Tylenol®, Motrin®, Zyrtec®, and Benadryl® products.
Jon Gelman is investigating cases involving Paxil users who have a child who suffered birth malformations after being exposed to Paxil within any trimester of pregnancy. Paxil and Paxil CR® are antidepressants manufactured by the pharmaceutical company GlaxoSmithKline.
FDA requires manufacturer of Botox® to post warning on its product of potential adverse reactions.
On July 10, 2009, Medtronic, Inc., announced a defect in the Paradigm® Quick-Set® Infusion Sets. The company identified a potentially high rate of failure of the system to function properly and deliver medication to the patient in an accurate manner through the pump.
In July 2008, the FDA announced a mandatory black box warning label for fluoroquinolone drugs that highlights and strengthens the warning for increased risk of tendonitis and tendon rupture
Jon L. Gelman LLC is investigating cases involving individuals who have suffered the loss of taste and smell (anosmia) after using Zicam®. Zicam® is an over-the-counter nasal spray used to relieve the symptoms associated with the common cold and flu and is manufactured by Matrixx Initiatives. Matrixx manufactures a range of products under the Zicam® name, but the name Zicam® is generally used to refer to its over-the-counter nasal zinc solution spray.
We are investigating cases in which Raptiva® users have experienced neurological changes including unusual weakness, loss of coordination and changes in vision.
On April 8, 2009, the drug manufacturer Genentech announced a phased withdrawal of the psoriasis drug Raptiva® (efalizumab) from the U.S. market.
The US Centers for Disease Control (CDC) has issued an alert for the spread of human swine flu virus. Employers and employees will now need to be alerted to preparations and the reactions that may occur.